Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

Trial Profile

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2019

At a glance

  • Drugs Galunisertib (Primary) ; Lomustine
  • Indications Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
    • 21 Nov 2018 Planned End Date changed from 31 Oct 2018 to 1 May 2019.
    • 11 Sep 2018 Planned End Date changed from 1 Oct 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top